Skip to main content

​Promethazine Hydrochloride Injection, USP 25mg/mL ampoules (XGen Pharmaceuticals DJB, USA)​

Section 19A approved medicine
​Promethazine Hydrochloride Injection, USP 25mg/mL ampoules (XGen Pharmaceuticals DJB, USA)​
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Current
Medicines in short supply/unavailable
DBL PROMETHAZINE HYDROCHLORIDE 50mg/2mL injection BP ampoule - ARTG 16255
Indication(s)

Promethazine Injection is indicated for the following conditions:

  • Treatment of allergic reactions such as:
    • uncomplicated allergic conditions of the immediate type, e.g., pruritus, urticaria and angioedema, when oral therapy is impossible or contraindicated.
  • Treatment and prevention of vomiting including:
    • motion sickness;
    • drug induced nausea;
    • prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery, such as procedures with a high incidence of post-operative vomiting (e.g., gynaecological surgery, strabismus or middle ear surgery, and electroconvulsive therapy); in patients with a past history of motion sickness or post-operative vomiting; and in patients in whom avoidance of vomiting is crucial (e.g., neurosurgery and eye surgery).

Promethazine has sedative effects and it is also used in pre-operative, post-operative and obstetric (during labour) sedation.

Images
Picture of ​Promethazine Hydrochloride Injection USP 25mg/mL ampoules - carton label